Revelation Biosciences adjusts warrant exercise price https://www.investing.com/news/company-news/revelation-biosciences-adjusts-warrant-exercise-price-93CH-3494577
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini | REVB Stock News Revelation Biosciences completes Phase 1 study for Gemini, showing promise in reducing acute kidney injury and infections. Top-line data on safety and immune response soon.
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy.
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024 Revelation Biosciences (NASDAQ: REVB ) just reported results for the first quarter of 2024. Revelation Biosciences reported earnings per share of -$2.46. This was below the analyst estimate for EPS of -$1.77. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024 appeared first on InvestorPlace .
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and.
Navigating Uncertainty: How Healthcare Reforms Pose Risks to Revelation Biosciences Inc. Revelation Biosciences Inc. (REVB) has disclosed a new risk, in the Regulation category. Revelation Biosciences Inc. faces significant risk due to …
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023 Revelation Biosciences (NASDAQ: REVB ) just reported results for the fourth quarter of 2023. Revelation Biosciences reported earnings per share of -$8.33. This was above the analyst estimate for EPS of -$13.77. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now. The post REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023 appeared first on InvestorPlace .
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results. Corporate Highlights Completed a $6.2 million public offering. Commencement of first in human Phase 1 clinical study of Gemini at the beginning of March. Oral prese.
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking.